Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 February;107(1) > Minerva Medica 2016 February;107(1):54-61

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

 

Minerva Medica 2016 February;107(1):54-61

 REVIEWS

Prognostic value of matrix metalloproteinase 9 in nasopharyngeal carcinoma: a meta-analysis

Dan LIAO 1, Haohai HUANG 2, Zhu ZHU 1, Tong LI 1, Huahui LI 1, Guo-Liang HUANG 1, Zhiwei HE 1

1 Sino-American Cancer Research Institute, Key Laboratory for Epigenetics of Dongguan City, Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Guangdong Medical University, Dongguan, China; 2 Department of Clinical Pharmacy, Dongguan Third People’s Hospital, Affiliated Dongguan Shilong People’s Hospital of Southern Medical University, Dongguan, Guangdong, China

INTRODUCTION: Recent studies have shown that matrix metalloproteinase 9 (MMP9) plays a vital role in tumor metastasis and is overexpressed in many human cancers. However, the prognostic value of MMP9 overexpression in nasopharyngeal carcinoma (NPC) is conflicting and heterogeneous. We therefore conducted a meta-analysis to investigate the association between MMP9 expression and the prognostic value in NPC.
EVIDENCE ACQUISITION: Relevant literature that evaluating the relationship between MMP-9 expression and the outcome of NPC patients were searched in PubMed, Embase, Cochrane, Ovid Medline and Chinese wanfang databases updated to May 2015. The primary study outcome was overall survival (OS). Secondary endpoint was disease-free survival (DFS). The combined hazard ratios (HRs) with their 95% confidence intervals (CIs) were assessed using STATA 12.0 software.
EVIDENCE SYNTHESIS: A total of 6 studies were included with the defined including and excluding criteria and subjected to meta-analysis. The pooled result showed that MMP9 overexpression was significantly associated with poor prognosis in terms of OS (HR: 1.65, 95% CI: 1.38-1.95, P<0.0001) and poor DFS (HR: 1.61, 95% CI: 1.28-2.02, P<0.0001) in NPC patients. Subgroup analysis suggested that high expression of MMP9 was associated with poor OS in NPC patients with different sample types. No evidence for publication bias was observed in our meta-analysis.
CONCLUSIONS: The current limited evidence suggests that increased MMP9 expression is associated with poor OS, and DFS in NPC. Therefore, we conclude that overexpression of MMP9 in both NPC tissue and blood sample might serve as an indicator of prognosis in NPC patients.

language: English


FULL TEXT  REPRINTS

top of page